中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

19 records (took 0.026 seconds)

    BIOMARKERS FOR THE DETECTION AND SCREENING OF DOWN SYNDROME
    1.
    发明申请
    BIOMARKERS FOR THE DETECTION AND SCREENING OF DOWN SYNDROME 失效
    生物标志物检测和筛查下行综合征

    公开(公告)号：US20120288873A1

    公开(公告)日：2012-11-15

    申请号：US13467661

    申请日：2012-05-09

    Applicant: Eleftherios P. Diamandis ,  Chan-Kyung Jane Cho ,  Eduardo Martinez Morillo

    Inventor： Eleftherios P. Diamandis ,  Chan-Kyung Jane Cho ,  Eduardo Martinez Morillo

    IPC: G01N33/566 ,  G01N21/82 ,  G01N21/64 ,  G01N27/62 ,  G01N33/573

    CPC classification number: G01N33/689 ,  C12Q1/37 ,  C12Q1/44 ,  G01N33/6893 ,  G01N2333/4725 ,  G01N2800/385 ,  G01N2800/387 ,  G01N2800/50

    Abstract: The disclosure includes assays and methods for screening for risk of Down syndrome and/or trisomy 21 in a fetus. The assays and methods comprise determining the level of at least one biomarker selected from mucin 13 (MUC13), bile salt-activated lipase (CEL), dipeptidyl peptidase 4 (DPP4), carboxypeptidase A1 (CPA1), amyloid precursor protein (APP) and tenascin-C (TNC-C) polypeptides in a test biological sample from a pregnant subject, wherein a decreased level of MUC13, CEL, DPP4, and/or CPA1 polypeptide and/or an increased level of APP and/or TNC-C polypeptide in the test biological sample compared to a corresponding reference biomarker polypeptide level indicates an increased risk of Down syndrome or trisomy 21 in the fetus. The disclosure also includes assays, compositions, immunoassays, and kits for performing the methods disclosed herein.

    Abstract translation: 该公开内容包括用于筛查胎儿唐氏综合征和/或21三体风险的测定和方法。 测定和方法包括确定选自粘蛋白13（MUC13），胆汁盐活化脂肪酶（CEL），二肽基肽酶4（DPP4），羧肽酶A1（CPA1），淀粉样蛋白前体蛋白（APP）和至少一种生物标志物的水平 来自怀孕受试者的测试生物样品中的腱生蛋白-C（Tasc-C）多肽，其中MUC13，CEL，DPP4和/或CPA1多肽的水平降低和/或增加的APP和/或TNC-C多肽水平 在测试生物样品中与相应的参考生物标志物多肽水平相比，表明唐氏综合征的风险增加或胎儿的21三体风险。 本公开还包括用于进行本文公开的方法的测定，组合物，免疫测定和试剂盒。

    Detection of prostate-specific antigen in breast tumors
    2.
    发明授权
    Detection of prostate-specific antigen in breast tumors 失效
    乳腺肿瘤中前列腺特异性抗原的检测

    公开(公告)号：US5688658A

    公开(公告)日：1997-11-18

    申请号：US532808

    申请日：1996-01-05

    Applicant: Eleftherios P. Diamandis

    Inventor： Eleftherios P. Diamandis

    IPC: G01N33/50 ,  C12Q1/42 ,  C12Q1/68 ,  G01N33/543 ,  G01N33/574 ,  G01N33/58 ,  G01N33/48 ,  G01N33/53

    CPC classification number: G01N33/57488 ,  C12Q1/6886 ,  G01N33/57415 ,  G01N33/582 ,  C12Q2600/106 ,  C12Q2600/112 ,  Y10S436/813

    Abstract: This invention relates to the detection of prostate-specific antigen (PSA) in female breast tumor extract as a prognostic or predictive indicator for breast carcinoma. The presence of prostate-specific antigen in breast tumors is associated with earlier disease stage, younger women and better survival. PSA is associated with tumors which have estrogen and/or progesteron receptors.

    Abstract translation: PCT No.PCT / CA94 / 00267 Sec。 371日期1996年1月5日 102（e）日期1996年1月5日PCT 1994年5月13日PCT公布。 第WO94 / 27152号公报 日期1994年11月24日本发明涉及女性乳腺肿瘤提取物中前列腺特异性抗原（PSA）检测作为乳腺癌的预后或预测指标。 乳腺肿瘤中前列腺特异性抗原的存在与早期疾病阶段，年轻女性和更好的生存相关。 PSA与具有雌激素和/或孕激素受体的肿瘤相关。

    Markers of the male urogenital tract
    3.
    发明授权
    Markers of the male urogenital tract 有权
    男性泌尿生殖道的标记

    公开(公告)号：US09040464B2

    公开(公告)日：2015-05-26

    申请号：US13814959

    申请日：2011-08-16

    Applicant: Keith Jarvi ,  Eleftherios P. Diamandis ,  Andrei Drabovich

    Inventor： Keith Jarvi ,  Eleftherios P. Diamandis ,  Andrei Drabovich

    IPC: G01N33/68 ,  C12Q1/68

    CPC classification number: G01N33/6893 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/68 ,  G01N33/689 ,  G01N2333/705 ,  G01N2333/78 ,  G01N2800/34 ,  G01N2800/342 ,  G01N2800/367

    Abstract: Methods for detecting urogenital conditions or urogenital status in a subject are described comprising measuring urogenital markers or polynucleotides encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for urogenital conditions, and kits for carrying out the methods of the invention. The invention also contemplates therapeutic applications for urogenital conditions employing urogenital markers, polynucleotides encoding the markers, and/or binding agents for the markers.

    Abstract translation: 描述了用于检测受试者中泌尿生殖器官状态或泌尿生殖状态的方法，包括测量来自受试者的样品中的编码标志物的泌尿生殖标志物或多核苷酸。 本发明还提供泌尿生殖条件的定位或成像方法，以及用于实施本发明方法的试剂盒。 本发明还考虑了使用泌尿生殖标志物，编码标记物的多核苷酸和/或标记物的结合剂的泌尿生殖条件的治疗应用。

    Detection of ovarian cancer
    5.
    发明授权
    Detection of ovarian cancer 失效
    检测卵巢癌

    公开(公告)号：US07741019B2

    公开(公告)日：2010-06-22

    申请号：US10415222

    申请日：2001-11-01

    Applicant: Eleftherios P. Diamandis ,  Liu-Ying Luo

    Inventor： Eleftherios P. Diamandis ,  Liu-Ying Luo

    IPC: C12Q1/00 ,  G01N33/574

    CPC classification number: G01N33/57449 ,  G01N2333/96455

    Abstract: A method for the diagnosis, prognosis, and monitoring of ovarian cancer in a subject by detecting hK10 in a sample from the subject, preferably a serum sample or tumor tissue extract. hK10 may be measured using a reagent that detects or binds to hK10 preferably antibodies specifically reactive with hK10 or a part thereof. Imaging methods for tumors associated with hK10 are also described using an agent that binds to hK10 which had a label for imaging the tumor.

    Abstract translation: 一种通过检测来自受试者的样品中的hK10，优选血清样品或肿瘤组织提取物来诊断，预后和监测受试者的卵巢癌的方法。 可以使用检测或结合hK10的试剂优选hK10，优选与hK10或其一部分特异性反应的抗体。 还使用与hK10结合的试剂描述与hK10相关的肿瘤的成像方法，所述试剂具有用于成像肿瘤的标记。

    Localization and therapy of non-prostatic endocrine cancer with agents directed against prostate specific antigen
    6.
    发明授权
    Localization and therapy of non-prostatic endocrine cancer with agents directed against prostate specific antigen 有权
    使用针对前列腺特异性抗原的药物进行非前列腺内分泌癌的定位和治疗

    公开(公告)号：US06274118B1

    公开(公告)日：2001-08-14

    申请号：US09543582

    申请日：2000-04-05

    Applicant: Eleftherios P. Diamandis ,  Russell Redshaw

    Inventor： Eleftherios P. Diamandis ,  Russell Redshaw

    IPC: A61K5100

    CPC classification number: A61K49/16 ,  A61K51/08 ,  A61K51/1051

    Abstract: It was discovered that prostate-specific antigen is produced by non-prostatic endocrine cancers. It was further discovered that non-prostatic endocrine cancers with steroid receptors can be stimulated with steroids to cause them to produce PSA either initially or at increased levels. This invention relates to the imaging of non-prostatic endocrine cancers by labelled biological binding units which bind to prostate-specific antigen in an imaging procedure, such as, radio imaging or magnetic resonance imaging. Further, the PSA-binding units may be constructed to deliver a toxic agent, such as a radioisotope, toxin or a drug to provide endocrine cancer therapy. Another aspect of the invention is passive immunotherapy against endocrine cancers by treatment with PSA-binding units.

    Abstract translation: 发现前列腺特异性抗原由非前列腺内分泌癌产生。 进一步发现，具有类固醇受体的非前列腺内分泌癌可以用类固醇刺激以使其最初或以更高的水平产生PSA。 本发明涉及通过在成像过程中结合前列腺特异性抗原的标记的生物结合单位如无线电成像或磁共振成像对非前列腺内分泌癌的成像。 此外，可以构建PSA结合单元以输送毒性剂，例如放射性同位素，毒素或药物以提供内分泌癌症治疗。 本发明的另一方面是通过用PSA-结合单元处理而对内分泌癌的被动免疫治疗。

    METHODS AND COMPOSITIONS FOR THE DETECTION OF OVARIAN CANCER
    8.
    发明申请
    METHODS AND COMPOSITIONS FOR THE DETECTION OF OVARIAN CANCER 审中-公开
    检测卵巢癌的方法和组成

    公开(公告)号：US20110256560A1

    公开(公告)日：2011-10-20

    申请号：US13125272

    申请日：2009-10-20

    Applicant: Eleftherios P. Diamandis ,  Cynthia Kuk

    Inventor： Eleftherios P. Diamandis ,  Cynthia Kuk

    IPC: G01N33/566

    CPC classification number: G01N33/57449 ,  G01N33/57488 ,  G01N33/6842 ,  G01N2800/50 ,  G01N2800/52 ,  G01N2800/54

    Abstract: Provided is a method of screening for, diagnosing or detecting ovarian cancer in a subject comprising (a) determining a level of mdogen-2 in a test sample from the subject, and (b) comparing the level of mdogen-2 in the test sample with a control, where detecting an increase in the level of mdogen-2 in the test sample compared to the control is indicative of ovarian cancer in the subject.

    Abstract translation: 本发明提供了筛选，诊断或检测受试者的卵巢癌的方法，其包括（a）确定来自受试者的测试样品中mdogen-2的水平，和（b）比较测试样品中mdogen-2的水平 与对照相比，检测样品中mdogen-2水平与对照相比增加的对照表明受试者的卵巢癌。

    Localization and therapy of non-prostatic endocrine cancer with agents directed against prostate specific antigen
    10.
    发明授权
    Localization and therapy of non-prostatic endocrine cancer with agents directed against prostate specific antigen 失效
    使用针对前列腺特异性抗原的药物进行非前列腺内分泌癌的定位和治疗

    公开(公告)号：US6068830A

    公开(公告)日：2000-05-30

    申请号：US569206

    申请日：1996-04-11

    Applicant: Eleftherios P. Diamandis ,  Russell Redshaw

    Inventor： Eleftherios P. Diamandis ,  Russell Redshaw

    IPC: A61K49/16 ,  A61K51/08 ,  A61K51/10 ,  A61K51/00 ,  A61K49/00 ,  G01N31/00 ,  G01N33/48

    CPC classification number: A61K49/16 ,  A61K51/08 ,  A61K51/1051

    Abstract: It was discovered that prostate-specific antigen is produced by non-prostatic endocrine cancers. It was further discovered that non-prostatic endocrine cancers with steroid receptors can be stimulated with steroids to cause them to produce PSA either initially or at increased levels. This invention relates to the imaging of non-prostatic endocrine cancers by labelled biological binding units which bind to prostate-specific antigen in an imaging procedure, such as, radioimaging or magnetic resonance imaging. Further, the PSA-binding units may be constructed to deliver a toxic agent, such as a radioisotope, toxin or a drug to provide endocrine cancer therapy. Another aspect of the invention is passive immunotherapy against endocrine cancers by treatment with PSA-binding units.

    Abstract translation: PCT No.PCT / CA94 / 00392 Sec。 371日期：1996年4月11日 102（e）日期1996年4月11日PCT 1994年7月14日PCT公布。 出版物WO95 / 02424 日期1995年1月26日发现前列腺特异性抗原由非前列腺内分泌癌产生。 进一步发现，具有类固醇受体的非前列腺内分泌癌可以用类固醇刺激以使其最初或以更高的水平产生PSA。 本发明涉及通过在成像过程（例如放射成像或磁共振成像）中结合前列腺特异性抗原的标记的生物结合单位对非前列腺内分泌癌的成像。 此外，可以构建PSA结合单元以输送毒性剂，例如放射性同位素，毒素或药物以提供内分泌癌症治疗。 本发明的另一方面是通过用PSA-结合单元处理而对内分泌癌的被动免疫治疗。

Patent Agency Ranking